Roche Reports registry Data for Benralizumab in Cervical cancer

Roche today announced registry results for benralizumab in patients with cervical cancer. The study demonstrated that benralizumab reduces hospitalization rates compared to standard of care or placebo. These results provide important insights into the treatment of cervical cancer and support the continued development of benralizumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.